KOSDAQMachinery475960

Tomocube

₩22,250▼ 2.84%2026-11-18 close
Market Cap
₩299.8B
Turnover
₩2.5B
Volume
110K
Shares out.
13.5M
PER
—
PBR
10.7×
EPS
-₩280
Dividend Yield
0.00%

PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q4–2026Q3) · Dividend yield is based on ₩0 per share · Prices as of the 2026-11-18 close

01

Report overview

Tomocube: Revenue Up, Losses Persist Ahead of Breakeven Test

Tomocube's 2025 revenue rose to KRW 11.3 billion, but operating losses (KRW 5.57 billion in 2025) have now run for three straight years, and losses have continued for three consecutive quarters through Q3 2026, making the breakeven target the next test.

  1. 1

    2025 revenue reached KRW 11.3 billion, up 90.4% from the prior year, and rose for two consecutive years from 2024 through 2025.

  2. 2

    Operating losses of KRW 6.73 billion (2023), KRW 8.78 billion (2024) and KRW 5.57 billion (2025) mark three straight loss years, with the 2025 loss narrower.

  3. 3

    Operating profit of KRW 398 million in Q4 2025 marked a turn to profit, but operating losses have continued in each of the three quarters from Q1 2026 to Q3 2026.

  4. 4

    HT products made up 87.9% of sales in the first nine months of 2026, and exports were about 60% (per a TipRanks report on the company's Q3 2026 disclosure).

  5. 5

    Kiwoom Securities said in an August 2026 report that it cut its target price to 61,000 won while maintaining a buy rating.

02

Business structure

Tomocube develops holographic tomography (HT) equipment that images cells in three dimensions, along with consumables and analysis software. Its research line-up centers on the high-end HT-X1 Plus and the mid-to-low-priced HT-X1 mini, while HT-R1 and HT-T1 are sold for inspection and measurement.

According to a TipRanks report on the company's third-quarter 2026 disclosure, HT products made up 87.9% of consolidated sales in the nine months to September 30, 2026, with consumables and services at 12.1%.

On the same basis, exports were about 60% and domestic sales about 40%, and HT products are used by about 200 institutions in more than 50 countries.

The company is organized into a Life Science division for biomedical equipment and a Precision division for measurement and inspection, each carrying operating responsibility, according to its March 2026 shareholder letter.

On the non-bio side, a supply contract signed at the end of 2024 with a display inspection equipment maker for industrial HT modules over two years was the first such order, and Money Today reported in August 2025 that part of it was reflected in Q2 2025 sales.

The company said in its March 2026 shareholder letter that it has completed development of a transmissive module for glass-substrate inspection and a reflective module for semiconductor inspection, and that it has moved into evaluation and pilot stages with major customers.

On software, subscription revenue from AI analysis software is growing, and management cites the rising share of consumables and software as evidence of a shift toward recurring revenue.

On competition, a Shinhan Securities analyst wrote in a December 2025 report that Tomocube is the only solution in organoid measurement without a competitor, and Money Today reported that its measurable thickness is about five times that of leading overseas rivals.

Daishin Securities noted in a December 2025 IPO report that the customer base is shifting from universities and research institutes toward big pharma and core labs.

03

Earnings trend

Quarterly revenue · Operating profit
RevenueOperating profit
Annual revenue · Operating profit
RevenueOperating profit
Quarterly results · Last 5 quarters
QuarterRevenueOperating profitOp. margin
2025Q3₩2.5B-₩1.8B−72.5%
2025Q4₩5B₩400M8.0%
2026Q1₩2.7B-₩1.9B−67.9%
2026Q2₩5B-₩600M−11.8%
2026Q3₩2.3B-₩1.8B−78.5%
Annual results
YearRevenueOperating profitNet income (parent)Op. marginROEDebt-to-equity
2023₩3.7B-₩6.7B-₩23.6B−179.7%−133.0%11.7%
2024₩5.9B-₩8.8B-₩8.3B−147.8%−19.8%3.9%
2025₩11.3B-₩5.6B-₩4.8B−49.3%−12.4%7.0%

Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-11-13

04

Earnings analysis

Annual revenue rose from KRW 3.75 billion in 2023 to KRW 5.94 billion in 2024 (up 58.5% year on year) and KRW 11.3 billion in 2025 (up 90.4%), rising for two consecutive years from 2024 through 2025, with 2025 the largest year of the 2023–2025 period.

Operating losses of KRW 6.73 billion in 2023 and KRW 8.78 billion in 2024 widened before narrowing to KRW 5.57 billion in 2025, which leaves three straight years of operating losses.

Operating margin improved from -179.7% in 2023 to -148% in 2024 (precisely -147.8%) and -49.3% in 2025, while the gross margin cited in the company's shareholder letter rose from 60.4% in 2024 to 65.8% in 2025.

Net loss attributable to controlling shareholders was KRW 23.6 billion in 2023, KRW 8.3 billion in 2024 and KRW 4.81 billion in 2025, a third straight loss year, and the total net loss including non-controlling interests was reported at the same amounts for each year.

Equity at the end of 2025 was KRW 38.8 billion, all attributable to controlling shareholders, and total liabilities were KRW 2.72 billion, giving a debt ratio of 7.0% for 2025. Operating cash flow was negative in each year: -KRW 5.93 billion in 2023, -KRW 6.54 billion in 2024 and -KRW 6.75 billion in 2025.

Quarterly sales went from KRW 2.52 billion in Q3 2025 to KRW 4.99 billion in Q4 2025 (up 97.8% quarter on quarter), then to KRW 2.75 billion in Q1 2026 (down 45.0%), KRW 4.96 billion in Q2 2026 (up 80.8%) and KRW 2.3 billion in Q3 2026 (down 53.7%, and down 8.8% year on year).

Operating profit of KRW 398 million in Q4 2025 marked a turn to profit, but operating losses returned at KRW 1.87 billion in Q1 2026, narrowed to KRW 587 million in Q2 2026 and widened again to KRW 1.81 billion in Q3 2026, which was still narrower than a year earlier.

Among the disclosed quarters, the largest controlling-shareholder net loss was KRW 2.84 billion in Q3 2026, and the controlling net loss for the last four quarters (Q4 2025 to Q3 2026) totals KRW 3.75 billion.

Across the five quarters from Q3 2025 to Q3 2026, Q4 2025 is the only quarter in which operating profit turned positive, and it was also the quarter with the highest sales at KRW 4.99 billion, so the margin structure remains the central issue.

05

Industry analysis

Tomocube's market has two halves: three-dimensional cell imaging equipment for biomedical research and drug development, and optical measurement equipment for semiconductor and display inspection.

On the bio side, Shinhan Securities wrote in a December 2025 report that clinical use of organoids could spread quickly over three to five years.

The company points to its measurement depth as a competitive edge, and a company profile cited by FnGuide describes an advantage in user convenience and image quality from features such as automatic stage mounting and background correction in under one second.

Money Today reported in August 2025 that non-bio sales were expected to be 10–15% of revenue that year, and that the company aims to raise that share to more than half within five years.

Industrial expansion depends on partnerships with inspection equipment makers, and the company has said that partner firms are building inspection systems with its modules.

Demand is lumpy: Kiwoom Securities reported that Q2 2026 orders were KRW 3.42 billion, down 30.0% from the prior quarter, and attributed part of the swing to June orders slipping into July.

Because the mid-to-low-priced HT-X1 mini sells mainly in Korea and Asia, price competition in Asia could show up quickly in the sales mix. Taken together, the company looks to be in a middle stage, where sales growth continues but order momentum has softened since Q2 2026.

06

Outlook

Tomocube said in its March 2026 shareholder letter that its goal for 2026 is an annual operating profit turnaround. Samsung Securities, in a March 2026 company update, cited a 2026 revenue target of KRW 20 billion and breakeven as the goal.

Kiwoom Securities, in an August 2026 report, projected 2026 revenue of KRW 20 billion with an operating loss of KRW 2.2 billion, and expected a turn to profit in 2027 with revenue of KRW 34.6 billion and operating profit of KRW 1.8 billion.

The IPO-stage 2026 revenue scenario was KRW 16.4 billion, and Daily Pharm reported in September 2026 that first-half 2026 revenue reached 47.1% of that figure.

Cumulative sales for the first nine months of 2026 are around KRW 10 billion, roughly half of the KRW 20 billion estimate cited by brokers, so Q4 2026 revenue is the nearest test of the full-year outlook.

The next-generation HT-X1 Max, which can measure up to 500 micrometers in thickness, was introduced in media coverage, and Kiwoom Securities gave a fourth-quarter 2026 launch timing.

On bio, Samsung Securities wrote in March 2026 that a joint study with a global big pharma company on HT-based organoid analysis would release results after the third quarter of 2026. Shinhan Securities expected growth to accelerate from 2027, when big pharma and non-bio volume production sales increase.

On the industrial side, the key checkpoint is whether partner-built inspection systems and customer evaluations convert into volume production contracts. Daishin Securities noted in December 2025 that long equipment lead times mean meaningful revenue contribution may become visible from the second half of 2027.

07

Valuation

PER
—
PBR
10.7×
ROE
-10.2%
EPS
-₩280
BPS
₩2,662
Dividend per share
₩0

Because the last four quarters show net losses, the price-to-earnings ratio cannot be calculated.

The price-to-book ratio sits in the zone of a large premium to net assets, and with all KRW 38.8 billion of equity attributable to controlling shareholders, the market is pricing in expected future earnings well above book value. The dividend yield is effectively zero, so a dividend-based comparison does not apply.

Broker estimates for 2026 from Kiwoom Securities and Samsung Securities also assume a turn to profit, which means earnings-based valuation comparisons become meaningful mainly after that turn.

Where earnings-based measures are not usable, revenue growth, order intake and the pace of operating-loss reduction serve as supporting indicators.

The fourth-quarter 2025 operating profit remains the reference point for the valuation debate, and because losses returned in 2026, whether the profit turn can be sustained is the central variable. A comparison with sector peer multiples would require a full year of profit as a basis.

PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-11-13

08

Bull factors

Sales growth and a profitable quarter

2025 revenue reached KRW 11.3 billion, up 90.4% year on year, and rose for two consecutive years from 2024. Operating profit of KRW 398 million in Q4 2025 marked a turn to profit. The company has set an annual turnaround to profit as its 2026 target. Cumulative sales for the first nine months of 2026 total around KRW 10 billion.

Improving profitability indicators

Operating margin improved from -179.7% in 2023 to -49.3% in 2025. The gross margin cited in the shareholder letter rose from 60.4% in 2024 to 65.8% in 2025. Kiwoom Securities said the Q2 2026 gross margin rose to 63.5%, up 2 percentage points from the prior quarter.

Overseas sales network and technical differentiation

HT products are used by about 200 institutions in more than 50 countries, with exports at about 60% of sales. A Shinhan Securities analyst wrote in a December 2025 report that the company is the only solution in organoid measurement without a competitor.

The company says its industrial glass-substrate and semiconductor inspection modules have entered evaluation and pilot stages with major customers.

09

Bear factors

Consecutive losses and a wider loss quarter

Operating losses have continued for three straight years from 2023, and operating losses have also persisted through the first three quarters of 2026. The Q3 2026 operating loss of KRW 1.81 billion widened from the prior quarter. The controlling net loss over the last four quarters totals KRW 3.75 billion. Operating cash flow was negative in each year from 2023 to 2025.

Quarterly sales swings and softer orders

Sales fell 45.0% quarter on quarter in Q1 2026 and 53.7% in Q3 2026. Kiwoom Securities said Q2 2026 orders of KRW 3.42 billion were down 30.0% from the prior quarter. Q3 2026 sales were also down 8.8% from a year earlier.

Valuation load and share supply

With net losses over the last four quarters, the price-to-book ratio sits in a zone of large premium to net assets. Kiwoom Securities noted that venture capital shares still held after the listing, about 12%, could drive short-term share price volatility.

Disclosures in November 2025 showed holdings by five insiders declining. An early investor, Hanmi Science, also sold its stake.

10

Risk factors

Delayed profit turnaround

Operating losses were KRW 1.87 billion in Q1 2026, KRW 587 million in Q2 2026 and KRW 1.81 billion in Q3 2026. If the breakeven target slips, operating costs will continue to draw on the funds raised at listing. Quarterly sales moving between KRW 2.3 billion and KRW 4.96 billion make it harder to absorb fixed costs. Whether the full-year target is reached depends on fourth-quarter sales.

Overseas sales and channel structure

With exports at about 60% of sales, quarterly revenue can swing with exchange rates and regional research budgets. The company set up a German subsidiary in 2025 and is expanding distributor sales, so its channel mix is still changing. A larger share of distributor sales could change the margin structure.

Industrial validation and technology competition

Glass-substrate and semiconductor inspection modules are still in evaluation and pilot stages, and volume production contracts have not been confirmed. Long equipment lead times could push the contribution from industrial sales to the second half of 2027 or later. Whether the company keeps its edge in organoid measurement also needs to be tracked.

11

What to watch next

  1. Q4 2026

    Whether the HT-X1 Max launches and how it sells. The key question is whether the 500-micrometer model extends the customer base and lifts average selling prices.

  2. After Q4 2026 (timing not fixed)

    Whether results from the joint organoid study with a global big pharma company are released. Commercial partnership could create linked revenue.

  3. Q4 2026

    Disclosures of volume production contracts for industrial modules and the move from pilot to supply. Whether evaluations by glass-substrate and semiconductor inspection customers turn into supply deals will shape the industrial revenue structure.

  4. End of March 2027

    The FY2026 annual report will show full-year revenue, operating loss and whether the company reached breakeven. The gap between broker estimates of around KRW 20 billion and actual results becomes the next benchmark.

  5. Mid-May 2027

    The Q1 2027 quarterly report will show whether losses continue. Whether the three-quarter run of operating losses ends would be the first sign of a turnaround.

12

Overall view

Tomocube's 2025 revenue of KRW 11.3 billion, up 90.4%, confirms growth at the top line. The operating loss narrowed to KRW 5.57 billion in 2025, but the company has not yet escaped a three-year pattern of operating losses. The Q4 2025 operating profit showed that a profitable quarter is possible.

However, quarterly sales moved between KRW 2.3 billion and KRW 4.96 billion in 2026, and operating losses continued for three consecutive quarters. Bullish factors include a rising export share, margin support from high-priced equipment and differentiation in organoid measurement.

Bearish factors include softer orders, volatile quarterly sales, persistent losses and a high price-to-book ratio. Broker estimates assume about KRW 20 billion of 2026 revenue, so Q4 2026 sales and the FY2026 annual report are the nearest tests.

Commercialization of industrial volume production and the reception of the HT-X1 Max remain variables that could change the medium-term revenue structure. The timing of the profit turn and order recovery are the next points to watch.

13

Sources

  1. Korea Exchange (KRX) — Prices · Market Cap · Volume
  2. FSS electronic disclosure system (DART) — Financial statements · Dividend filings
Show 15 more articles and sources
  1. tomocube.com
  2. comp.fnguide.com
  3. dailypharm.com
  4. buffettlab.co.kr
  5. money2.daishin.com
  6. mt.co.kr
  7. mt.co.kr
  8. newsvalue.kr
  9. etoday.co.kr
  10. goinsider.kr
  11. investing.com
  12. samsungpop.com
  13. seo.goover.ai
  14. tipranks.com
  15. valueline.co.kr

Report written 2026-11-13 · Data as of 2026-11-12

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.

Other reports in this industry

View industry analysis